Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Address: Av. Doutor Cardoso de Melo, 1.184, 17º andar Vila Olimpia São Paulo – SP – Brasil Cep: 04548-004,Brazil
Tel: +55 11 3568-3400
Web: http://www.biogenidec.com.br/
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology leader with products in oncology, neurology and immunology. Biogen Idec is committed to transforming scientific discoveries into advances and health care. The company’s include the discovery, research, development and biomanufacturing of medicine and a global commercial infrastructure.
Biogen Idec pursues the creativity of science with passion and discipline. For over 25 years, the company has grown through the discovery, development and commercialization of innovative products themselves and through strategic alliances.
Scientific excellence that achieves new standards of care drives the company’s work. Currently, more than twenty products are in clinical development to meet a number of important medical needs.
Biogen Idec has affiliates in Brazil, Canada, Australia, Japan and throughout Europe, including the international headquarters in Zug, Switzerland. The company currently employs approximately 3,600 people worldwide.
In Brazil, Biogen Idec is focused on the Multiple Sclerosis market, as an expert company in the disease, and is responsible for organizing World MS Day activities in the country.
Avonex, Tysabri
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
See our Cookie Privacy Policy Here